Comparative Pharmacology
Head-to-head clinical analysis: HIVID versus ZERIT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIVID versus ZERIT XR.
HIVID vs ZERIT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIVID (zalcitabine) is a nucleoside analogue reverse transcriptase inhibitor (NRTI). It is phosphorylated intracellularly to its active triphosphate form, which competes with endogenous deoxycytidine triphosphate for incorporation into viral DNA, leading to chain termination and inhibition of HIV reverse transcriptase.
ZERIT XR (stavudine extended-release) is a nucleoside analog reverse transcriptase inhibitor (NRTI). It is phosphorylated intracellularly to stavudine triphosphate, which competes with natural thymidine triphosphate for incorporation into viral DNA, causing chain termination and inhibition of HIV-1 reverse transcriptase.
0.75 mg orally every 8 hours.
ZERIT XR (stavudine extended-release) is administered orally once daily. Adult dose: 100 mg once daily for patients ≥60 kg; 75 mg once daily for patients <60 kg.
None Documented
None Documented
Terminal elimination half-life 3.5 hours (range 2.9-4.1 h), prolonged to 8-12 h in renal impairment (CrCl <30 mL/min)
5.7 hours (range 4–8 hours) in patients with normal renal function; prolonged to 13–20 hours in renal impairment (CrCl <30 mL/min).
Renal: 75% as unchanged drug; fecal: 18% as metabolites; biliary: <5%
Approximately 94% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; <1% is eliminated in feces.
Category C
Category C
Antiretroviral (NRTI)
Antiretroviral (NRTI)